Honors & News
June 22, 2010
A new grant from the National Psoriasis Foundation could help University of Rochester Medical Center (URMC) scientists find ways to forecast which patients with the red, flaky skin disorder are most likely to suffer from an arthritic disease that sometimes follows.
With the $200,000 grant, Christopher Ritchlin, M.D., M.P.H. and colleagues plan to spend two years following between 60 and 100 patients with both psoriasis and psoriatic arthritis. Over that time, they'll track how popular medications (like methotrexate and newer anti-TNF drugs) affect participants' levels of DC-STAMP - a molecule that plays a role in autoimmunity and the formation of osteoclasts, or bone-absorbing cells. Ritchlin's team, in concert with URMC professor of Orthopedics Edward Schwarz, Ph.D., was the first ever to implicate DC-STAMP as a potential biomarker for any form of arthritis, igniting a blaze of similar research in the field.
- Validation of Power Doppler Versus Contrast Enhanced Magnetic Resonance Imaging Quantification of Joint Inflammation in Murine Inflammatory Arthritis. J Bone Miner Res. In press. (2014 Oct 31).
- Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters. J Orthop Res. 32, 1389-96. (2014 Oct 01).
- TGF-beta1 Suppresses Plasmin and MMP Activity in Flexor Tendon Cells via PAI-1: Implications for Scarless Flexor Tendon Repair. J Cell Physiol. In press. (2014 Jun 24).